Legal Opinion
Janssen Pharmaceutica N.V. v. Teva Pharmaceuticals USA, Inc.
Court of Appeals for the Federal Circuit
Decided September 25, 2009No. Nos. 2008-1594, 2009-1070, 2009-1088PublishedCited by 35 opinions
1Opinion of the Court
DYK, Circuit Judge.
Janssen Pharmaceutica N.V., Janssen L.P., and Synaptech, Inc. (“Janssen”), appeal from a final judgment of the United States District Court for the District of Delaware. After a bench trial, the district court determined that the claims of U.S. Patent No. 4,663,318 (“the '318 patent”) were invalid for lack of enablement. In re '318 Patent Infringement Litig., 578 F.Supp.2d 711, 737 (D.Del.2008). We affirm.
BACKGROUND
Janssen’s '318 patent claims a method for treating Alzheimer’s disease with galanthamine. Claim 1 is representative. It claims “[a] method of treating…
2Cases cited18 opinions
- Sampson v. MurraySupreme Court of the United States · 1974
- Genentech, Inc. v. Novo Nordisk, A/s, Novo Nordisk of North America, Inc. And Novo Nordisk Pharmaceuticals, Inc.Court of Appeals for the Federal Circuit · 1997
- Atlas Powder Company v. E.I. Du Pont De Nemours & Company and Alamo Explosives Company, Inc.Court of Appeals for the Federal Circuit · 1984
- Invitrogen Corp. (Formerly Known as Life Technologies, Inc.) v. Clontech Laboratories, Inc.Court of Appeals for the Federal Circuit · 2005
- Brenner v. MansonSupreme Court of the United States · 1966
13 more not listed; retrieve them via the Exa API.
3Cited by35 opinions
- Green Edge Enterprises, LLC v. Rubber Mulch Etc., LLCCourt of Appeals for the Federal Circuit · 2010
- Nuvo Pharm. (Ireland) Designated Activity Co. v. Dr. Reddy's Labs. Inc.Court of Appeals for the Federal Circuit · 2019
- In Re MontgomeryCourt of Appeals for the Federal Circuit · 2012
- Erfindergemeinschaft UroPep GbR v. LillyDistrict Court, E.D. Texas · 2017
- Netgear, Inc. v. Ruckus Wireless, Inc.District Court, D. Delaware · 2013
30 more not listed; retrieve them via the Exa API.